Back to All News


PRISM Vision Group® Affiliated Physicians Are Among the First in the Country To Treat Previously Untreatable Patients With New Groundbreaking FDA Approved Medication

Drs. Howard Fine of NJRetina (NJR) and Jordana Fein of The Retina Group of Washington (RGW) are among the first physicians in the nation to utilize SYFOVRE™ (pegcetacoplan injection). Approved in mid-February, this is the first and only treatment available for Geographic Atrophy, which is a leading cause of blindness.

Howard F. Fine, M.D., Retina Specialist and Vitreoretinal Surgeon with NJRetina, who treated the first patient in New Jersey, commented; “I am delighted we are now able to offer treatment to patients with geographic atrophy (GA) from dry age-related macular degeneration (AMD). This blinding eye disease is a large public health problem, affecting about 1 million Americans. NJRetina and I were involved in the clinical trials which showed significant reductions in disease progression and will be a game-changer for our patients.”

Jordana G. Fein, M.D., M.S., Retina Specialist of The Retina Group of Washington (RGW) who treated the first patient in the DC area,  stated; “I am excited to be able to deliver this groundbreaking, new treatment for advanced macular degeneration to our patients. Until the approval last Friday, there were no therapeutic options for patients with geographic atrophy, which is a progressive and blinding form of macular degeneration. This is a first in class medication which reduces the rate of the progression of this disease. I was privileged to be involved in the clinical trials that led to the FDA approval of Syfovre™ and am hopeful that our patients will benefit from this new therapeutic option.”

Steven Madreperla, M.D., Ph.D., President and CEO of PRISM Vision Group added: “This is truly a great day. As a Retina Surgeon, I am thrilled that a treatment is now available for the many patients we take care of with geographic atrophy. As the President and CEO of PRISM Vision group, I am incredibly proud of our clinicians to be some of the first in the nation to utilize this treatment as well as all those on our team that led and participated in the clinical trials that led to Syfovre’s FDA approval. Our doctor’s dedication to the progression of the science of medicine through our robust clinical trials program is one of the many things that sets PRISM apart.”

To learn more about PRISM Vision group, please visit

To learn more about NJRetina and Dr. Fine please visit

To learn more about The Retina Group of Washington and Dr. Fein please visit


About PRISM Vision Group®
PRISM Vision Group® is the largest vertically integrated independent ophthalmology administrative services organization (ASO) operating exclusively on the east coast. PRISM affiliates provide eye care in over 90 locations, with 170 providers and over 1300 employees throughout New Jersey, Pennsylvania, Delaware, Virginia, Maryland and the District of Columbia. PRISM Vision Group is a physician-led organization with a mission to support practices in providing patients with world-class, comprehensive eye care in an unrivaled practice environment for its network of affiliated physicians and employees.

Back to All News